i-Lens
Cipla Ltd Share Price
SECTOR : Pharmaceuticals | BSE :500087 | NSE : CIPLA
Aug 08, 2022 04:01 PM
Pharmaceuticals firm Cipla Announced Q1FY23 Result :
“I am pleased to see the sustained momentum across our key segments with strong secondary growth across geographies. The core portfolio momentum in One-India business continues to be robust driven by strong demand levers. Our US run rate continues to witness consistent traction in respiratory, complex generics and peptide portfolio. We are closely tracking upcoming complex launches in H2FY23. Our reported operating profitability of 21.3% is well within our full year guidance of 21-22% range and has grown double digit vs last year base EBITDA despite multiple cost headwinds. Our cost rigor and calibrated pricing actions have helped offset inflationary cost elements, insulate margins while maintaining high serviceability.” Umang Vohra MD and Global CEO, Cipla Ltd
| Date | Action Type | Ratio |
|---|---|---|
| Aug 08, 2022 | Dividend | 250 |
| Aug 09, 2021 | Dividend | 250 |
| Mar 19, 2020 | Dividend | 150 |
Cipla Limited is a pharmaceutical company having a market capitalization of Rs. 73,307.57 crores as of 18th August 2021. The company was incorporated within the year 1935. It reported its consolidated revenue at Rs. 5,504.35 for the quarter ended June 2021. The Bombay Stock Exchange (BSE) and National Stock Exchange have assigned the number 500087 and scrip code CIPLA, respectively. As of 18th August 2021, the shares of Cipla were trading at Rs. 908.85.
Cipla is headquartered in Mumbai and produces products for various therapeutic areas, including cardiology, children’s health, dermatology & cosmetology, diabetes, HIV/AIDS, infectious illnesses & critical care, malaria, and so on. The drug company primarily develops medicines to treat respiratory, disorders, arthritis, diabetes, weight control and depression, and other medical conditions. Cipla is the third-largest drug company within the country and is present in most countries within the European region, with DTMs in Germany, Norway, UK, and Spain. The company’s promoters hold a 36.72% stake of the total shareholding in the company in June 2021 as against 36.68% in June 2020 with zero pledge. However, the mutual funds holding has also decreased in the last 12 months, decreasing from 16.29% in June 2020 to 13.36% in June 2021, and over the last 3 months, it has decreased 1.28%.
In June 2021, consolidated total revenue from operations grew 26.64% to Rs. 5,504.35 crores, against Rs. 4,346.16 crores within the corresponding quarter last year. The Indian major pharmaceutical has posted a 23.67% increase in the consolidated net profit of Rs. 714.72 crores, on strong sales performance during June 2021, it had posted a net profit of Rs. 577.91 Crores within the corresponding period of the previous fiscal. EBITDA rose 28% to Rs. 1,346 crores in June 2021, from Rs. 1,049 crores in June 2020. EBITDA margin improved 32 basis points to 24.5%, as against 24.1% in the year-ago period. EPS of the company was Rs. 8.86 as compared to Rs. 5.13 in March 2021. Cipla’s shares closed at 908.85 (NSE) on 18th August 2021 and have returned 18.83% over the last 12 months.
Cipla House Peninsula Buss Par, Ganpatrao Kadam Mg Lower Parel, Mumbai, Maharashtra, 400013
| Tel | : | 91-22-24826000 |
| : | cosecretary:cipla.com | |
| Website | : | http://www.cipla.com |
Karvy Computershare Pvt Ltd
| AGM Date (Month) | : | Aug |
| Face Value Equity Shares | : | 2 |
| Market Lot Equity Shares | : | 1 |
| BSE Code | : | 500087 |
| NSE Code | : | CIPLA |
| Book Closure Date (Month) | : | Aug |
| BSE Group | : | A |
| ISIN | : | INE059A01026 |
